Enalapril prevents chemo cardiotoxicity
Prophylactic use of ACE inhibitors may prevent cardiotoxicity caused by high-dose chemotherapy, according to a study published in Circulation. The study randomized 114 chemotherapy patients whose troponin I levels rose following chemotherapy to ACE inhibitor or observation arms. The ACE inhibitor group exhibited no study-defined cardiotoxicity (10% units decline in heart pumping efficiency) compared to 43% of patients in the control group. Only enalapril was evaluated, but "I believe that an ACE inhibitor class effect, rather than a specific enalapril effect, is responsible for our study results," study lead author Daniela Cardinale (European Institute of Oncology) said...
You may also be interested in...
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.